Abstract
There is growing interest in the ability of phytochemicals to prevent chronic diseases, such as cancer and heart disease. However, some of these agents have poor bioavailability and many of the in-depth studies into their mechanisms of action have been carried out in vitro using doses which are unachievable in humans. In order to optimize the design of chemopreventive treatment, it is important to determine which of the many reported mechanisms of action are clinically relevant. In this review we consider the physiologically achievable doses for a few of the best studied agents (indole-3-carbinol, diindolylmethane, curcumin, epigallocatechin-3-gallate and resveratrol) and summarize the data derived from studies using these low concentrations in cell culture. We then cite examples of in vitro effects which have been observed in vivo. Finally, the ability of agent combinations to act synergistically or antagonistically is considered. We conclude that each of the compounds shows an encouraging range of activities in vitro at concentrations which are likely to be physiologically relevant. There are also many examples of in vivo studies which validate in vitro observations. An important consideration is that combinations of agents can result in significant activity at concentrations where any single agent is inactive. Thus, for each of the compounds reviewed here, in vitro studies have provided useful insights into their mechanisms of action in humans. However, data are lacking on the full range of activities at low doses in vitro and the benefits or otherwise of combinations in vivo.
Similar content being viewed by others
Article PDF
References
Manson MM . Inhibition of survival signalling by dietary polyphenols and indole-3-carbinol. Eur J Cancer 2005; 41: 1842–53.
Aggarwal BB, Shishodia S . Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71: 1397–421.
Surh YJ . Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 3: 768–80.
Sepkovic DW, Bradlow HL, Bell MC . Quantitative determination of 3,3′-diindolylmethane in urine of individuals receiving indole-3-carbinol. Nutr Cancer 2001; 42: 57–63.
Reed GA, Arneson DW, Putnam WC, Smith HJ, Gray JC, Sullivan DK, et al. Single-dose and multiple-dose administration of in-dole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmethane. Cancer Epidemiol Biomarkers Prev 2006; 15: 2477–81.
Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF . Pilot study: Effect of 3,3′-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer 2004; 50: 161–7.
Bell MC, Crowley-Nowick P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynaecol Oncol 2000; 78: 123–9.
Bradlow HL, Michnovicz JJ, Halper M, Miller DG, Wong GYC, Osborne MP . Long-term responses of women to indole-3-carbinol or a high fiber diet. Cancer Epidemiol Biomarkers Prev 1994; 3: 591–5.
McAlindon TE, Gulin J, Chen T, Klug T, Lahita R, Nuite M . Indole-3-carbinol in women with SLE: effect on estrogen metabolism and disease activity. Lupus 2001; 10: 779–83.
Michnovicz JJ . Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol. Int J Obes 1998; 22: 227–9.
Michnovicz JJ, Adlercreutz H, Bradlow HL . Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J Natl Cancer Inst 1997; 89: 718–23.
Michnovicz JJ, Bradlow HL . Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. Nutr Cancer 1991; 16: 59–66.
Rosen CA, Bryson PC . Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J Voice 2004; 18: 248–53.
Naik R, Nixon S, Lopes A, Godfrey K, Hatem MH, Monaghan JM . A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia. Int J Gynecol Cancer 2006; 16: 786–90.
Wong GYC, Bradlow L, Sepkovic D, Mehl S, Mailman J, Osborne MP . Dose-ranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem Suppl 1997; 28/29: 111–6.
Reed GA, Peterson KS, Smith HJ, Gray JC, Sullivan DK, Mayo MS, et al. A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev 2005; 14: 1953–60.
Shertzer HG, Berger ML, Tabor MW . Intervention in free-radical mediated hepatotoxicity and lipid-peroxidation by in-dole-3-carbinol. Biochem Pharmacol 1988; 37: 333–8.
Stresser DM, Williams DE, Griffin DA, Bailey GS . Mechanisms of tumor modulation by indole-3-carbinol. Disposition and excretion in male Fischer 344 rats. Drug Metab Disp 1995; 23: 965–75.
Yu Z, Mahadevan B, Lohr C V, Fischer KA, Louderback MA, Krueger SK, et al. Indole-3-carbinol in the maternal diet provides chemoprotection for the fetus against transplacental carcinogenesis by the polycyclic aromatic hydrocarbon, dibenzo[a, l]pyrene. Carcinogenesis 2006; 27: 2116–23.
Anderton MJ, Manson MM, Verschoyle RD, Gescher A, Lamb JH, Farmer PB, et al. Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin Cancer Res 2004; 10: 5233–41.
Anderton MJ, Manson MM, Verschoyle R, Gescher A, Steward WP, Williams ML, et al. Physiological modeling of formulated and crystalline 3,3′-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Disp 2004; 32: 632–8.
Crowell JA, Page JG, Levine BS, Tomlinson MJ, Hebert CD . Indole-3-carbinol, but not its major digestive product 3,3′-diindolylmethane, induces reversible hepatocyte hypertrophy and cytochromes P450. Toxicol Appl Pharmacol 2006; 211: 115–23.
Donald S, Verschoyle RD, Greaves P, Colombo T, Zucchetti M, Falcioni C, et al. Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma. Int J Cancer 2004; 111: 961–7.
Leibelt DA, Hedstrom OR, Fischer KA, Pereira CB, Williams DE . Evaluation of chronic dietary exposure to indole-3-carbinol and absorption-enhanced 3,3′-diindolylmethane in spraguedawley rats. Toxicol Sci 2003; 74: 10–21.
Zhang X, Malejka-Giganti D . Effects of treatment of rats with indole-3-carbinol on apoptosis in the mammary gland and mammary adenocarcinomas. Anticancer Res 2003; 23: 2473–79.
Parkin DR, Malejka-Giganti D . Differences in the hepatic P450-dependent metabolism of estrogen and tamoxifen in response to treatment of rats with 3,3′-diindolylmethane and its parent compound indole-3-carbinol. Cancer Detect Prev 2004; 28: 72–9.
Chen I, McDougal A, Wang F, Safe S . Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 1998; 19: 1631–39.
Hestermann E V, Brown M . Agonist and chemopreventative ligands induce differential transcriptional cofactor recruitment by aryl hydrocarbon receptor. Mol Cell Biol 2003; 23: 7920–25.
Liu S, Abdelrahim M, Khan S, Ariazi E, Jordan VC, Safe S . Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells. Biol Chem 2006; 387: 1209–13.
Jellinck PH, Forkert P-G, Riddick DS, Okey AB, Michnovicz JJ, Bradlow HL . Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem Pharmacol 1993; 45: 1129–36.
Li Y, Li X, Sarkar FH . Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. J Nutr 2003; 133: 1011–19.
Meng Q, Yuan F, Goldberg ID, Rosen EM, Auborn K, Fan S . Indole-3-carbinol is a negative regulator of estrogen receptor-a signalling in human tumor cells. J Nutr 2000; 130: 2927–31.
Sundar SN, Kerekatte V, Equinozio CN, Doan VB, Bjeldanes LF, Firestone GL . Indole-3-carbinol selectively uncouples expression and activity of estrogen receptor subtypes in human breast cancer cells. Mol Endocrinol 2006; 20: 3070–82.
Riby JE, Chang GHF, Firestone GL, Bjeldanes LF . Ligand-independent activation of estrogen receptor function by 3,3′-diindolylmethane in human breast cancer cells. Biochem Pharmacol 2000; 60: 167–77.
Leong H, Firestone GL, Bjeldanes LF . Cytostatic effects of 3, 3′-diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated increase in transforming growth factor-α expression. Carcinogenesis 2001; 22: 1809–17.
Leong H, Riby JE, Firestone GL, Bjeldanes LF . Potent ligand-independent estrogen receptor activation by 3,3′-diindolyl-methane is mediated by cross talk between the protein kinase A and mitogen-activated protein kinase signaling pathways. Mol Endocrinol 2004; 18: 291–302.
Wang TT, Milner MJ, Milner JA, Kim YS . Estrogen receptor alpha as a target for indole-3-carbinol. J Nutr Biochem 2006; 17: 659–64.
Le HT, Schaldach CM, Firestone GL, Bjeldanes LF . Plant-derived 3,3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem 2003; 278: 21 136–45.
Hsu JC, Zhang J, Dev A, Wing A, Bjeldanes LF, Firestone GL . Indole-3-carbinol inhibition of androgen receptor expression and down-regulation of androgen responsiveness in human prostate cancer cells. Carcinogenesis 2005; 26: 1896–904.
Moiseeva EP, Fox LH, Howells LM, Temple LA, Manson MM . Indole-3-carbinol-induced death in cancer cells involves EGFR downregulation and is exacerbated in a 3D environment. Apopto-sis 2006; 11: 799–812.
Moiseeva EP, Heukers R, Manson MM . EGFR and Src are involved in indole-3-carbinol-induced death and cell cycle arrest of human breast cancer cells. Carcinogenesis 2007; 28: 435–45.
Howells LM, Hudson EA, Manson MM . Inhibition of phosphati-dylinositol 3-kinase/protein kinase B signaling is not sufficient to account for indole-3-carbinol-induced apoptosis in some breast and prostate tumor cells. Clin Cancer Res 2005; 11: 8521–27.
Fan S, Meng Q, Auborn K, Carter T, Rosen EM . BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer 2006; 94: 407–26.
Gong Y, Firestone GL, Bjeldanes LF . 3,3′-diindolylmethane is a novel topoisomerase IIalpha catalytic inhibitor that induces S-phase retardation and mitotic delay in human hepatoma HepG2 cells. Mol Pharmacol 2006; 69: 1320–27.
Gong Y, Sohn H, Xue L, Firestone GL, Bjeldanes LF . 3,3′-Diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells. Cancer Res 2006; 66: 4880–87.
Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S . 3, 3′-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 2006; 27: 717–28.
Savino JA, 3rd, Evans JF, Rabinowitz D, Auborn KJ, Carter TH . Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolyl-methane. Mol Cancer Ther 2006; 5: 556–63.
Xue L, Firestone GL, Bjeldanes LF . DIM stimulates IFNγ gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways. Oncogene 2005; 24: 2343–53.
Rahman KMW, Li Y, Sarkar FH . Inactivation of Akt and NF-κB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr Cancer 2004; 48: 84–94.
Rahman KMW, Sarkar FH . Inhibition of nuclear translocation of nuclear factor-κB contributes to 3,3′-diindolylmethane-in-duced apoptosis in breast cancer cells. Cancer Res 2005; 65: 364–71.
Li Y, Chinni SR, Sarkar FH . Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci 2005; 10: 236–43.
Takada Y, Andreeff M, Aggarwal BB . Indole-3-carbinol suppresses NF-kappaB and I{kappa}B{alpha} kinase activation causing inhibition of expression of NF-kappaB-regulated anti-apoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood 2005; 106: 641–9.
Bhuiyan MM, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S, et al. Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 2006; 66: 10 064–72.
IARC. Handbooks of cancer prevention; No 9. Cruciferous vegetables, isothiocyanates and indoles. Lyon: IARC Press; 2004.
Grubbs CJ, Steele VE, Casebolt T, Juliana MM, Eto I, Whitaker LM, et al. Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res 1995; 15: 709–16.
Chen DZ, Qi M, Auborn KJ, Carter TH . Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV-16 transgenic preneoplastic cervical epithelium. J Nutr 2001; 131: 3294–302.
Bradlow HL, Michnovicz JJ, Telang NT, Osborne MP . Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 1991; 12: 1571–74.
McMahon M, Itoh K, Yamamoto M, Chanas SA, Henderson CJ, McLellan LI, et al. The Cap‘n’Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res 2001; 61: 3299–307.
Chanas SA, Jiang Q, McMahon M, McWalter GK, McLellan LI, Elcombe CR, et al. Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem J 2002; 365: 405–16.
Katchamart S, Stresser DM, Dehal SS, Kupfer D, Williams DE . Concurrent flavin-containing monooxygenase down-regulation and cytochrome P-450 induction by dietary indoles in rat: implications for drug-drug interaction. Drug Metab Disp 2000; 28: 930–6.
Katchamart S, Williams DE . Indole-3-carbinol modulation of hepatic monooxygenases CYP1A1, CYP1A2 and FMO1 in guinea pig, mouse and rabbit. Comp Biochem Physiol Part C 2001; 129: 377–84.
Manson MM, Hudson EA, Ball HWL, Barrett MC, Clark HL, Judah DJ, et al. Chemoprevention of aflatoxin B1-induced car-cinogenesis by indole-3-carbinol in rat liver - predicting the outcome using early biomarkers. Carcinogenesis 1998; 19: 1829–36.
Park J-Y, Bjeldanes LF . Organ-selective induction of cytochrome P-450-dependent activities by indole-3-carbinol-derived products: influence on covalent binding of benzo[a]pyrene to hepatic and pulmonary DNA in the rat. Chem Biol Interact 1992; 83: 235–47.
Hudson EA, Howells LM, Gallacher-Horley B, Fox LH, Gescher A, Manson MM . Growth-inhibitory effects of the chemopreven-tive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line. BMC Cancer 2003; 3: 2.
Rahman KM, Sarkar FH, Banerjee S, Wang Z, Liao DJ, Hong X, et al. Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Mol Cancer Ther 2006; 5: 2747–56.
Arora A, Shukla Y . Modulation of vinca-alkaloid induced P-glycoprotein expression by indole-3-carbinol. Cancer Lett 2003; 189: 167–73.
Arora A, Seth K, Kalra N, Shukla Y . Modulation of P-glycopro-tein-mediated multidrug-resistance in K562 leukemic cells by indole-3-carbinol. Toxicol Appl Pharmacol 2005; 202: 237–43.
Christensen JG, LeBlanc GA . Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole-3-carbinol. Cancer Res 1996; 56: 574–81.
Auborn KJ, Fan S, Rosen EM, Goodwin L, Chandraskaren A, Williams DE, et al. Indole-3-carbinol is a negative regulator of estrogen. J Nutr 2003; 133: S2470–5.
Cover CM, Hsieh SJ, Cram EJ, Hong C, Riby JE, Bjeldanes LF, et al. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 1999; 59: 1244–51.
Malejka-Giganti D, Parkin DR, Bennett KK, Lu Y, Decker RW, Niehans GA, et al. Suppression of mammary gland carcinogen-esis by post-initiation treatment of rats with tamoxifen or in-dole-3-carbinol or their combination. Eur J Cancer Prev 2007; 16: 130–41.
Nho CW, Jeffery E . The synergistic upregulation of phase II detoxification enzymes by glucosinolate breakdown products in cruciferous vegetables. Toxicol Appl Pharmacol 2001; 174: 146–52.
Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 2001; 61: 1058–64.
Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002; 11: 105–11.
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21: 2895–900.
Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10: 6847–54.
Garcea G, Berry D P, Jones DJ, Singh R, Dennison AR, Farmer PB, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005; 14: 120–5.
Sharma RA, Ireson CR, Verschoyle RD, Hill KA, Williams ML, Leuratti C, et al. Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res 2001; 7: 1452–8.
Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, et al. Chemopreventive efficacy and pharmacoki-netics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2002; 11: 535–40.
Ravindranath V, Chandrasekhara N . Absorption and tissue distribution of curcumin in rats. Toxicol 1980; 16: 259–65.
Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ . Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidyl-choline. Cancer Chemother Pharmacol 2006; 60: 171–7.
Liu A, Lou H, Zhao L, Fan P . Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal 2006; 40: 720–7.
Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK . Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 2007; 330: 155–63.
Li L, Ahmed B, Mehta K, Kurzrock R . Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 2007; 6: 1276–82.
Li L, Braiteh FS, Kurzrock R . Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005; 104: 1322–31.
Bisht S, Feldmann G, Soni S, Ravi R, Karikari C, Maitra A, et al. Polymeric nanoparticle-encapsulated curcumin (nanocurcumin): a novel strategy for human cancer therapy. J Nanobiotechnol 2007; 5: 3.
Aggarwal BB, Kumar A, Bharti AC . Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363–98.
Elattar TM, Virji AS . The inhibitory effect of curcumin, genistein, quercetin and cisplatin on the growth of oral cancer cells in vitro. Anticancer Res 2000; 20: 1733–8.
Squires MS, Hudson EA, Howells L, Sale S, Houghton CE, Jones JL, et al. Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochem Pharmacol 2003; 65: 361–76.
Samaha HS, Kelloff GJ, Steele V, Rao CV, Reddy BS . Modulation of apopt osis by sul inda c, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 1997; 57: 1301–5.
Rao CV, Rivenson A, Simi B, Reddy BS . Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995; 55: 259–66.
Mahmoud NN, Carothers AM, Grunberger D, Bilinski RT, Churchill MR, Martucci C, et al. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 2000; 21: 921–7.
Chuang SE, Cheng AL, Lin JK, Kuo ML . Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food Chem Toxicol 2000; 38: 991–5.
Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB . Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-êB-regulated gene products. Cancer Res 2007; 67: 3853–61.
Inano H, Onoda M . Prevention of radiation-induced mammary tumors. Int J Radiat Oncol Biol Phys 2002; 52: 212–23.
Frank N, Knauft J, Amelung F, Nair J, Wesch H, Bartsch H . No prevention of liver and kidney tumors in Long-Evans Cinnamon rats by dietary curcumin, but inhibition at other sites and of metastases. Mutat Res 2003; 523-524: 127–35.
Menon LG, Kuttan R, Kuttan G . Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett 1995; 95: 221–5.
Busquets S, Carbo N, Almendro V, Quiles MT, Lopez-Soriano FJ, Argiles JM . Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Lett 2001; 167: 33–8.
Verma SP, Salamone E, Goldin B . Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by estro-genic pesticides. Biochem Biophys Res Commun 1997; 233: 692–6.
Lev-Ari S, Zinger H, Kazanov D, Yona D, Ben-Yosef R, Starr A, et al. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic ad-enocarcinoma cells. Biomed Pharmacother 2005; 59 ( Suppl 2): S276–80.
Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 2005; 11: 6738–44.
Khafif A, Schantz SP, Chou TC, Edelstein D, Sacks PG . Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalig-nant and malignant human oral epithelial cells. Carcinogenesis 1998; 19: 419–24.
Li N, Chen X, Liao J, Yang G, Wang S, Josephson Y, et al. Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 2002; 23: 1307–13.
Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA, et al. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther 2003; 2: 95–103.
Howells LM, Mitra A, Manson MM . Comparison of oxaliplatin-and curcumin-mediated antiproliferative effects in colorectal cell lines. Int J Cancer 2007; 121; 175–83.
Kamat AM, Sethi G, Aggarwal BB . Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther 2007; 6: 1022–30.
Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ . Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 2002; 62: 3868–75.
Lambert JD, Yang CS . Mechanisms of cancer prevention by tea constituents. J Nutr 2003; 133: S3262–7.
Chow HH, Cai Y, Alberts DS, Hakim I, Dorr R, Shahi F, et al. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 2001; 10: 53–8.
Nakagawa K, Okuda S, Miyazawa T . Dose-dependent incorporation of tea catechins, (-)-epigallocatechin-3-gallate and (-)-epigallocatechin, into human plasma. Biosci Biotechnol Biochem 1997; 61: 1981–5.
Unno T, Kondo K, Itakura H, Takeo T . Analysis of (-)-epigallocatechin gallate in human serum obtained after ingesting green tea. Biosci Biotechnol Biochem 1996; 60: 2066–68.
Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003; 9: 3312–9.
Dvorakova K, Dorr RT, Valcic S, Timmermann B, Alberts DS . Pharmacokinetics of the green tea derivative, EGCG, by the topical route of administration in mouse and human skin. Cancer Chemother Pharmacol 1999; 43: 331–5.
Yang CS, Lee MJ, Chen L . Human salivary tea catechin levels and catechin esterase activities: implication in human cancer prevention studies. Cancer Epidemiol Biomarkers Prev 1999; 8: 83–9.
Yang CS, Kim S, Yang GY, Lee MJ, Liao J, Chung J Y, et al. Inhibition of carcinogenesis by tea: bioavailability of tea poly-phenols and mechanisms of actions. Proc Soc Exp Biol Med 1999; 220: 213–7.
Fang JY, Hung CF, Hwang TL, Huang YL . Physicochemical characteristics and in vivo deposition of liposome-encapsulated tea catechins by topical and intratumor administrations. J Drug Target 2005; 13: 19–27.
Fang JY, Lee WR, Shen SC, Huang YL . Effect of liposome encapsulation of tea catechins on their accumulation in basal cell carcinomas. J Dermatol Sci 2006; 42: 101–9.
Lambert JD, Hong J, Kim DH, Mishin VM, Yang CS . Piperine enhances the bioavailability of the tea polyphenol (-)-epigallo-catechin-3-gallate in mice. J Nutr 2004; 134: 1948–52.
Kohri T, Nanjo F, Suzuki M, Seto R, Matsumoto N, Yamakawa M, et al. Synthesis of (-)-[4-3H]epigallocatechin gallate and its metabolic fate in rats after intravenous administration. J Agric Food Chem 2001; 49: 1042–8.
Vaidyanathan JB, Walle T . Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res 2001; 18: 1420–5.
Suganuma M, Okabe S, Oniyama M, Tada Y, Ito H, Fujiki H . Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis 1998; 19: 1771–6.
Cai Y, Anavy ND, Chow HH . Contribution of presystemic hepatic extraction to the low oral bioavailability of green tea catechins in rats. Drug Metab Dispos 2002; 30: 1246–9.
Baliga MS, Meleth S, Katiyar SK . Growth inhibitory and anti-metastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clin Cancer Res 2005; 11: 1918–27.
Lu YP, Lou YR, Xie JG, Peng QY, Liao J, Yang CS, et al. Topical applications of caffeine or (-)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc Natl Acad Sci USA 2002; 99: 12 455–60.
Ogasawara M, Matsunaga T, Suzuki H . Differential effects of antioxidants on the in vitro invasion, growth and lung metastasis of murine colon cancer cells. Biol Pharm Bull 2007; 30: 200–4.
Schwartz JL, Baker V, Larios E, Chung FL . Molecular and cellular effects of green tea on oral cells of smokers: a pilot study. Mol Nutr Food Res 2005; 49: 43–51.
Dong Z . Effects of food factors on signal transduction pathways. Biofactors 2000; 12: 17–28.
Cao Y, Cao R . Angiogenesis inhibited by drinking tea. Nature 1999; 398: 381.
Klaunig JE, Xu Y, Han C, Kamendulis LM, Chen J, Heiser C, et al. The effect of tea consumption on oxidative stress in smokers and nonsmokers. Proc Soc Exp Biol Med 1999; 220: 249–54.
Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A . Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006; 66: 1234–40.
Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E, Fujiki H . Synergistic effects of (-)-epigallocatechin gallate with (-)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res 1999; 59: 44–7.
Adhami VM, Malik A, Zaman N, Sarfaraz S, Siddiqui IA, Syed DN, et al. Combined inhibitory effects of green tea polyphe-nols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2007; 13: 1611–9.
Masuda M, Suzui M, Weinstein IB . Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2001; 7: 4220–9.
Masuda M, Suzui M, Lim JT, Weinstein IB . Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res 2003; 9: 3486–91.
Orner GA, Dashwood WM, Blum CA, Diaz GD, Li Q, Dashwood RH . Suppression of tumorigenesis in the Apc(min) mouse: down-regulation of beta-catenin signaling by a combination of tea plus sulindac. Carcinogenesis 2003; 24: 263–7.
Ohishi T, Kishimoto Y, Miura N, Shiota G, Kohri T, Hara Y, et al. Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane. Cancer Lett 2002; 177: 49–56.
Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram N P, Shishodia S, Takada Y . Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004; 24: 2783–840.
Baur JA, Sinclair DA . Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493–506.
Bhat KP, Pezzuto JM . Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci 2002; 957: 210–29.
Asensi M, Medina I, Ortega A, Carretero J, Bano MC, Obrador E, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002; 33: 387–98.
de Santi C, Pietrabissa A, Mosca F, Pacifici GM . Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 2000; 30: 1047–54.
Fremont L . Biological effects of resveratrol. Life Sci 2000; 66: 663–73.
Boocock DJ, Faust GES, Patel KR, Schinas AM, Brown VA, Ducharme MP, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16: 1246–52.
Boocock DJ, Patel KR, Faust GE, Normolle DP, Marczylo TH, Crowell JA, et al. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848: 182–7.
Goldberg DM, Yan J, Soleas GJ . Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003; 36: 79–87.
Wang LX, Heredia A, Song H, Zhang Z, Yu B, Davis C, et al. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J Pharm Sci 2004; 93: 2448–57.
Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS, et al. Human, rat, and mouse metabolism of resveratrol. Pharm Res 2002; 19: 1907–14.
Miksits M, Maier-Salamon A, Aust S, Thalhammer T, Reznicek G, Kunert O, et al. Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. Xenobiotica 2005; 35: 1101–19.
Sabolovic N, Humbert AC, Radominska-Pandya A, Magdalou J . Resveratrol is efficiently glucuronidated by UDP-glucuronosyl-transferases in the human gastrointestinal tract and in Caco-2 cells. Biopharm Drug Dispos 2006; 27: 181–9.
De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM . Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica 2000; 30: 857–66.
Regev-Shoshani G, Shoseyov O, Bilkis I, Kerem Z . Glycosylation of resveratrol protects it from enzymic oxidation. Biochem J 2003; 374: 157–63.
Kuhnle G, Spencer JP, Chowrimootoo G, Schroeter H, Debnam ES, Srai SK, et al. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 2000; 272: 212–7.
Jannin B, Menzel M, Berlot J P, Delmas D, Lancon A, Latruffe N . Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem Pharmacol 2004; 68: 1113–8.
Marier JF, Vachon P, Gritsas A, Zhang J, Moreau J P, Ducharme MP . Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 2002; 302: 369–73.
Vitrac X, Desmouliere A, Brouillaud B, Krisa S, Deffieux G, Barthe N, et al. Distribution of [14C]-trans-resveratrol, a cancer chemo-preventive polyphenol, in mouse tissues after oral administration. Life Sci 2003; 72: 2219–33.
Sale S, Verschoyle RD, Boocock D, Jones DJ, Wilsher N, Ruparelia KC, et al. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resvera-trol and the synthetic analogue trans 3,4,5,4'-tetramethoxy-stilbene. Br J Cancer 2004; 90: 736–44.
Abd El-Mohsen M, Bayele H, Kuhnle G, Gibson G, Debnam E, Kaila Srai S, et al. Distribution of [3H]trans-resveratrol in rat tissues following oral administration. Brit J Nutr 2006; 96: 62–70.
Wenzel E, Soldo T, Erbersdobler H, Somoza V . Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 2005; 49: 482–94.
Poolman TM, Ng LL, Farmer PB, Manson MM . Inhibition of the respiratory burst by resveratrol in human monocytes: correlation with inhibition of PI3K signaling. Free Radic Biol Med 2005; 39: 118–32.
Whitehead TP, Robinson D, Allaway S, Syms J, Hale A . Effect of red wine ingestion on the antioxidant capacity of serum. Clin Chem 1995; 41: 32–5.
Garvin S, Ollinger K, Dabrosin C . Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 2006; 231: 113–22.
Carbo N, Costelli P, Baccino FM, Lopez-Soriano FJ, Argiles JM . Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun 1999; 254: 739–43.
Chen Y, Tseng SH, Lai HS, Chen WJ . Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery 2004; 136: 57–66.
Tseng SH, Lin SM, Chen JC, Su YH, Huang HY, Chen CK, et al. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res 2004; 10: 2190–202.
Banerjee S, Bueso-Ramos C, Aggarwal BB . Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxy-genase 2, and matrix metalloprotease 9. Cancer Res 2002; 62: 4945–54.
Martin AR, Villegas I, Sanchez-Hidalgo M, de la Lastra CA . The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 2006; 147: 873–85.
Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP, Gescher AJ . Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4'-tetra-methoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int J Cancer 2005; 115: 194–201.
Provinciali M, Re F, Donnini A, Orlando F, Bartozzi B, Di Stasio G, et al. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer 2005; 115: 36–45.
Tessitore L, Davit A, Sarotto I, Caderni G . Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 2000; 21: 1619–22.
Sengottuvelan M, Viswanathan P, Nalini N . Chemopreventive effect of trans-resveratrol — a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydra-zine induced colon carcinogenesis. Carcinogenesis 2006; 27: 1038–46.
Kweon S, Kim Y, Choi H . Grape extracts suppress the formation of preneoplastic foci and activity of fatty acid synthase in rat liver. Exp Mol Med 2003; 35: 371–8.
Delmas D, Rebe C, Micheau O, Athias A, Gambert P, Grazide S, et al. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 2004; 23: 8979–86.
Fulda S, Debatin KM . Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2004; 23: 6702–11.
Fulda S, Debatin KM . Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mito-chondrial signalling. Eur J Cancer 2005; 41: 786–98.
Kubota T, Uemura Y, Kobayashi M, Taguchi H . Combined effects of resveratrol and paclitaxel on lung cancer cells. Anti-cancer Res 2003; 23: 4039–46.
Rezk YA, Balulad SS, Keller RS, Bennett JA . Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol 2006; 194: e23–6.
Awad AB, Burr AT, Fink CS . Effect of resveratrol and beta-sitosterol in combination on reactive oxygen species and prostaglandin release by PC-3 cells. Prostag Leukotr Ess 2005; 72: 219–26.
Mertens-Talcott SU, Percival SS . Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. Cancer Lett 2005; 218: 141–51.
Lee SH, Kim JS, Yamaguchi K, Eling TE, Baek SJ . Indole-3-carbinol and 3,3′ diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem Biophys Res Comm 2005; 328: 63–9.
Howells LM, Gallacher-Horley B, Houghton CE, Manson MM, Hudson EA . Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL 100 line. Mol Cancer Ther 2002; 1: 1161–72.
Lee IJ, Han F, Baek J, Hisatsune A, Kim KC . Inhibition of MUC1 expression by indole-3-carbinol. Int J Cancer 2004; 109: 810–16.
Telang NT, Katdare M, Bradlow HL, Osborne MP, Fishman J . I nhibition of pr olifera tion and modu lation of estradiol metabolism: novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol. Proc Soc Exp Biol Med 1997; 216: 246–52.
Rahman KMW, Aranha O, Glazyrin A, Chinni SR, Sarkar FH . Translocation of Bax to mitochondria induces apoptotic cell death in Indole-3-carbinol (I3C) treated breast cancer cells. Oncogene 2000; 19: 5764–71.
Ge X, Fares FA, Yannai S . Induction of apoptosis in MCF-7 cells by indole-3-carbinol is independent of p53 and Bax. Anticancer Res 1999; 19: 3199–204.
Cover CM, Hsieh SJ, Tran SH, Hallden G, Kim GS, Bjeldanes LF, et al. Indole-3-carbinol inhibits the expression of cyclin-depen-dent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signalling. J Biol Chem 1998; 273: 3838–47.
Ashok BT, Chen Y, Liu X, Bradlow HL, Mittelman A, Tiwari RK . Abrogation of estrogen-mediated cellular and biochemical effects by indole-3-carbinol. Nutr Cancer 2001; 41: 180–7.
Niwa T, Swaneck G, Bradlow HL . Alterations in estradiol metabolism in MCF-7 cells induced by treatment with indole-3-carbinol and related compounds. Steroids 1994; 59: 523–7.
Tiwari RK, Guo L, Bradlow HL, Telang NT, Osborne MP . Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent. J Natl Cancer Inst 1994; 86: 126–31.
Ashok BT, Chen YG, Liu X, Garikapaty VPS, Seplowitz R, Tschorn J, et al. Multiple molecular targets of indole-3-carbinol, a chemopreventive anti-estrogen in breast cancer. Eur J Cancer Prev 2002; 11: S86–93.
Garcia HH, Brar GA, Nguyen DHH, Bjeldanes LF, Firestone GL . Indole-3-carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex. J Biol Chem 2005; 280: 8756–64.
Rahman KMW, Aranha O P, Sarkar FH . Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells. Nutr Cancer 2003; 45: 101–12.
Meng QH, Goldberg ID, Rosen EM, Fan SJ . Inhibitory effects of indole-3-carbinol on invasion and migration in human breast cancer cells. Breast Cancer Res Treat 2000; 63: 147–52.
Chinni SR, Sarkar FH . Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin Cancer Res 2002; 8: 1228–36.
Jeon KI, Rih JK, Kim HJ, Lee YJ, Cho CH, Goldberg ID, et al. Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. FEBS Lett 2003; 544: 246–51.
Pappa G, Lichtenberg M, Iori R, Barillari J, Bartsch H, Gerhauser C . Comparison of growth inhibition profiles and mechanisms of apoptosis induction in human colon cancer cell lines by isothiocyanates and indoles from Brassicaceae. Mutat Res 2006; 599: 76–87.
Hong C, Firestone GL, Bjeldanes LF . Bcl-2 family-mediated apoptotic effects of 3,3′-diindolylmethane (DIM) in human breast cancer cells. Biochem Pharmacol 2002; 63: 1085–97.
Ge X, Yannai S, Rennert G, Gruener N, Fares FA . 3,3′-Diindolyl-methane induces apoptosis in human cancer cells. Biochem Biophys Res Commun 1996; 228: 153–8.
Hong C, Kim HA, Firestone GL, Bjeldanes LF . 3,3′-Diindolyl-methane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis 2002; 23: 1297–305.
Rahman KW, Li Y, Wang Z, Sarkar SH, Sarkar FH . Gene expression profiling revealed survivin as a target of 3,3′-diindolyl-methane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 2006; 66: 4952–60.
Nachshon-Kedmi M, Yannai S, Haj A, Fares FA . Indole-3-carbinol and 3,3′-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol 2003; 41: 745–52.
Garikapaty VP, Ashok BT, Tadi K, Mittelman A, Tiwari RK . 3, 3′-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. Biochem Biophys Res Commun 2006; 340: 718–25.
Gamet-Payrastre L, Lumeau S, Gasc N, Cassar G, Rollin P, Tulliez J . Selective cytostatic and cytotoxic effects of glucosinolates hydrolysis products on human colon cancer cells in vitro. Anti-cancer Drugs 1998; 9: 141–8.
Sanderson JT, Slobbe L, Lansbergen GWA, Safe S, van den Berg M . 2,3,7,8-tetrachlorodibenzo-p-dioxin and diindolylmethanes differentially induce cytochrome P450 1A1, 1B1, and 19 in H295R human adrenocortical carcinoma cells. Toxicol Sci 2001; 61: 40–8.
Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004; 90: 1011–5.
Lao CD, Ruffin MTT, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6: 10.
Wahlstrom B, Blennow G . A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 1978; 43: 86–92.
Holder GM, Plummer JL, Ryan AJ . The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 1978; 8: 761–8.
Ravindranath V, Chandrasekhara N . Metabolism of curcumin-studies with [3H]curcumin. Toxicol 1981; 22: 337–44.
Pan MH, Huang TM, Lin JK . Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999; 27: 486–94.
Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH . Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 853: 183–9.
Mori H, Niwa K, Zheng Q, Yamada Y, Sakata K, Yoshimi N . Cell proliferation in cancer prevention; effects of preventive agents on estrogen-related endometrial carcinogenesis model and on an in vitro model in human colorectal cells. Mutat Res 2001; 480–481: 201–7.
Collett GP, Campbell FC . Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2004; 25: 2183–9.
Scott DW, Loo G . Curcumin-induced GADD153 gene up-regulation in human colon cancer cells. Carcinogenesis 2004; 25: 2155–64.
Chen A, Xu J . Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol 2005; 288: G447–56.
Chen A, Xu J, Johnson AC . Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 2006; 25: 278–87.
Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ . Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999; 20: 445–51.
Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999; 18: 6013–20.
Goel A, Boland CR, Chauhan DP . Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001; 172: 111–8.
Hong J, Bose M, Ju J, Ryu JH, Chen X, Sang S, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004; 25: 1671–9.
Lin LI, Ke YF, Ko YC, Lin JK . Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. Oncol 1998; 55: 349–53.
Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G . Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 2002; 512: 334–40.
Simon A, Allais DP, Duroux JL, Basly JP, Durand-Fontanier S, Delage C . Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships. Cancer Lett 1998; 129: 111–6.
Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar S V, Limtrakul PN . Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 2002; 64: 573–82.
Han SS, Chung ST, Robertson DA, Ranjan D, Bondada S . Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, sand p53. Clin Immunol 1999; 93: 152–61.
Chen YR, Tan TH . Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 1998; 17: 173–8.
Kuo ML, Huang TS, Lin JK . Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Biochim Biophys Acta 1996; 1317: 95–100.
Bharti AC, Donato N, Aggarwal BB . Curcumin (diferuloyl-methane) inhibits constitutive and IL-6-inducible STAT3 phos-phorylation in human multiple myeloma cells. J Immunol 2003; 171: 3863–71.
Yang CS, Chen L, Lee MJ, Balentine D, Kuo MC, Schantz SP . Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 1998; 7: 351–4.
Meng X, Sang S, Zhu N, Lu H, Sheng S, Lee MJ, et al. Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans, mice, and rats. Chem Res Toxicol 2002; 15: 1042–50.
Lee MJ, Maliakal P, Chen L, Meng X, Bondoc FY, Prabhu S, et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 2002; 11: 1025–32.
Ullmann U, Haller J, Decourt JP, Girault N, Girault J, Richard-Caudron AS, et al. A single ascending dose study of epigallo- catechin gallate in healthy volunteers. J Int Med Res 2003; 31: 88–101.
Van Amelsvoort JM, Van Hof KH, Mathot JN, Mulder TP, Wiersma A, Tijburg LB . Plasma concentrations of individual tea catechins after a single oral dose in humans. Xenobiotica 2001; 31: 891–901.
Warden BA, Smith LS, Beecher GR, Balentine DA, Clevidence BA . Catechins are bioavailable in men and women drinking black tea throughout the day. J Nutr 2001; 131: 1731–7.
Chow HH, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, Chew WM, et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 2005; 11: 4627–33.
Henning SM, Niu Y, Liu Y, Lee NH, Hara Y, Thames GD, et al. Bioavailability and antioxidant effect of epigallocatechin gal-late administered in purified form versus as green tea extract in healthy individuals. J Nutr Biochem 2005; 16: 610–6.
Lambert JD, Lee MJ, Lu H, Meng X, Hong JJ, Seril DN, et al. Epigallocatechin-3-gallate is absorbed but extensively glucuro-nidated following oral administration to mice. J Nutr 2003; 133: 4172–7.
Chen L, Lee MJ, Li H, Yang CS . Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab Dispos 1997; 25: 1045–50.
Jeong WS, Kim IW, Hu R, Kong AN . Modulation of AP-1 by natural chemopreventive compounds in human colon HT-29 cancer cell line. Pharm Res 2004; 21: 649–60.
Jung YD, Kim MS, Shin BA, Chay KO, Ahn BW, Liu W, et al. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 2001; 84: 844–50.
McLoughlin P, Roengvoraphoj M, Gissel C, Hescheler J, Certa U, Sachinidis A . Transcriptional responses to epigallocatechin-3-gallate in HT 29 colon carcinoma spheroids. Genes Cells 2004; 9: 661–9.
Nam S, Smith DM, Dou QP . Ester bond-containing tea polyphe-nols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001; 276: 13322–30.
Hussain T, Gupta S, Adhami VM, Mukhtar H . Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int J Cancer 2005; 113: 660–9.
Siddiqui IA, Adhami VM, Afaq F, Ahmad N, Mukhtar H . Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J Cell Biochem 2004; 91: 232–42.
Gupta S, Ahmad N, Nieminen AL, Mukhtar H . Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000; 164: 82–90.
Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek D F, Kay NE . VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gal-late (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004; 104: 788–94.
Balasubramanian S, Efimova T, Eckert RL . Green tea polyphenol stimulates a Ras, MEKK1, MEK3, and p38 cascade to increase activator protein 1 factor-dependent involucrin gene expression in normal human keratinocytes. J Biol Chem 2002; 277: 1828–36.
Barthelman M, Bair WB 3rd, Stickland KK, Chen W, Timmermann BN, Valcic S, et al. (-)-Epigallocatechin-3-gallate inhibition of ultraviolet B-induced AP-1 activity. Carcinogenesis 1998; 19: 2201–4.
Chen W, Dong Z, Valcic S, Timmermann BN, Bowden GT . Inhibition of ultraviolet B — induced c-fos gene expression and p38 mitogen-activated protein kinase activation by (-)-epigallo-catechin gallate in a human keratinocyte cell line. Mol Carcinog 1999; 24: 79–84.
Nihal M, Ahmad N, Mukhtar H, Wood GS . Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer 2005; 114: 513–21.
Nomura M, Kaji A, He Z, Ma WY, Miyamoto K, Yang CS, et al. Inhibitory mechanisms of tea polyphenols on the ultraviolet B-activated phosphatidylinositol 3-kinase-dependent pathway. J Biol Chem 2001; 276: 46624–31.
Nomura M, Ma W, Chen N, Bode AM, Dong Z . Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced NF-kappaB activation by tea polyphenols, (-)-epigallocatechin gallate and theaflavins. Carcinogenesis 2000; 21: 1885–90.
Dong Z, Ma W, Huang C, Yang CS . Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins. Cancer Res 1997; 57: 4414–9.
Liang YC, Lin-shiau SY, Chen CF, Lin JK . Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epider-moid carcinoma cells. J Cell Biochem 1997; 67: 55–65.
Gupta S, Hastak K, Afaq F, Ahmad N, Mukhtar H . Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene 2004; 23: 2507–22.
Ahmad N, Gupta S, Mukhtar H . Green tea polyphenol epigallo-catechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch Biochem Biophys 2000; 376: 338–46.
Sah JF, Balasubramanian S, Eckert RL, Rorke EA . Epigallo-catechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem 2004; 279: 12755–62.
Bhimani RS, Troll W, Grunberger D, Frenkel K . Inhibition of oxidative stress in HeLa cells by chemopreventive agents. Cancer Res 1993; 53: 4528–33.
Chen JJ, Ye ZQ, Koo MW . Growth inhibition and cell cycle arrest effects of epigallocatechin gallate in the NBT-II bladder tumour cell line. BJU Int 2004; 93: 1082–6.
Khafif A, Schantz SP, al-Rawi M, Edelstein D, Sacks PG . Green tea regulates cell cycle progression in oral leukoplakia. Head Neck 1998; 20: 528–34.
Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, et al. Tea poly-phenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003; 63: 7563–70.
Lamy S, Gingras D, Beliveau R . Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res 2002; 62: 381–5.
Tang FY, Nguyen N, Meydani M . Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. Int J Cancer 2003; 106: 871–8.
El Bedoui J, Oak MH, Anglard P, Schini-Kerth VB . Catechins prevent vascular smooth muscle cell invasion by inhibiting MT1-MMP activity and MMP-2 expression. Cardiovasc Res 2005; 67: 317–25.
Dashwood WM, Carter O, Al-Fageeh M, Li Q, Dashwood RH . Lysosomal trafficking of beta-catenin induced by the tea polyphenol epigallocatechin-3-gallate. Mutat Res 2005; 591: 161–72.
Moon Y, Lee M, Yang H . Involvement of early growth response gene 1 in the modulation of microsomal prostaglandin E synthase 1 by epigallocatechin gallate in A549 human pulmonary epithelial cells. Biochem Pharmacol 2007; 73: 125–35.
Yu HN, Shen SR, Yin JJ . Effects of interactions of EGCG and Cd (2+) on the growth of PC-3 cells and their mechanisms. Food Chem Toxicol 2007; 45: 244–9.
Kalfon L, Youdim MB, Mandel SA . Green tea polyphenol (-)-epigallocatechin-3-gallate promotes the rapid protein kinase C-and proteasome-mediated degradation of Bad: implications for neuroprotection. J Neurochem 2007; 100: 992–1002.
Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK . High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 1377–82.
Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi PP, et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 2005; 49: 495–504.
Meng X, Maliakal P, Lu H, Lee MJ, Yang CS . Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 2004; 52: 935–42.
Juan ME, Lamuela-Raventos RM, de la Torre-Boronat MC, Planas JM . Determination of trans-resveratrol in plasma by HPLC. Anal Chem 1999; 71: 747–50.
Hsieh TC, Wu JM . Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 1999; 249: 109–15.
Aziz MH, Kumar R, Ahmad N . Cancer chemoprevention by resveratrol: In vitro and in vivo studies and the underlying mechanisms. Int J Oncol 2003; 23: 17–28.
Cao Z, Fang J, Xia C, Shi X, Jiang BH . trans-3,4,5′-Trihydroxy-stibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res 2004; 10: 5253–63.
Kaneuchi M, Sasaki M, Tanaka Y, Yamamoto R, Sakuragi N, Dahiya R . Resveratrol suppresses growth of Ishikawa cells through down-regulation of EGF. Int J Oncol 2003; 23: 1167–72.
Lee JE, Safe S . Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochem Pharmacol 2001; 62: 1113–24.
El-Mowafy AM, Alkhalaf M . Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. Carcinogenesis 2003; 24: 869–73.
Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM . Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 2001; 61: 7456–63.
Basly JP, Marre-Fournier F, Le Bail JC, Habrioux G, Chulia AJ . Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci 2000; 66: 769–77.
Scarlatti F, Sala G, Somenzi G, Signorelli P, Sacchi N, Ghidoni R . Resveratrol induces growth inhibition and apoptosis in meta-static breast cancer cells via de novo ceramide signaling. FASEB J 2003; 17: 2339–41.
Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998; 273: 21875–82.
Shih A, Davis FB, Lin HY, Davis PJ . Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK- and p53-dependent mechanism. J Clin Endocrinol Metab 2002; 87: 1223–32.
She QB, Huang C, Zhang Y, Dong Z . Involvement of c-jun NH (2)-terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol Carcinogenesis 2002; 33: 244–50.
She QB, Ma WY, Wang M, Kaji A, Ho CT, Dong Z . Inhibition of cell transformation by resveratrol and its derivatives: differential effects and mechanisms involved. Oncogene 2003; 22: 2143–50.
Woo JH, Lim JH, Kim YH, Suh SI, Min DS, Chang JS, et al. Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene 2004; 23: 1845–53.
Igura K, Ohta T, Kuroda Y, Kaji K . Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett 2001; 171: 11–6.
Ahmad N, Adhami VM, Afaq F, Feyes DK, Mukhtar H . Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res 2001; 7: 1466–73.
Ahmad KA, Clement MV, Hanif IM, Pervaiz S . Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res 2004; 64: 1452–59.
Huang C, Ma WY, Goranson A, Dong Z . Resveratrol suppresses cell transformation and induces apoptosis through a p53-depen-dent pathway. Carcinogenesis 1999; 20: 237–42.
Manna SK, Mukhopadhyay A, Aggarwal BB . Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000; 164: 6509–19.
Berge G, Ovrebo S, Botnen I V, Hewer A, Phillips DH, Haugen A, et al. Resveratrol inhibits benzo[a]pyrene-DNA adduct formation in human bronchial epithelial cells. Brit J Cancer 2004; 91: 333–8.
Hsieh TC, Wang Z, Hamby C V, Wu JM . Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem Biophys Res Commun 2005; 334: 223–30.
Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD . Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 2005; 4: 1465–74.
Author information
Authors and Affiliations
Corresponding author
Additional information
The corresponding author's laboratory is supported by the UK Medical Research Council and the EU Network of Excellence, ECNIS.
Rights and permissions
About this article
Cite this article
Howells, L., Moiseeva, E., Neal, C. et al. Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol Sin 28, 1274–1304 (2007). https://doi.org/10.1111/j.1745-7254.2007.00690.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00690.x
Keywords
This article is cited by
-
Indole glucosinolates exhibit anti-inflammatory effects on Ehrlich ascites carcinoma cells through modulation of inflammatory markers and miRNAs
Molecular Biology Reports (2021)
-
Antitumor Activity of Curcumin-Green Synthesized Gold Nanoparticles: In Vitro Study
BioNanoScience (2019)
-
Mode of treatment governs curcumin response on doxorubicin-induced toxicity in cardiomyoblasts
Molecular and Cellular Biochemistry (2018)
-
Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer
BMC Cancer (2015)
-
Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells
BMC Complementary and Alternative Medicine (2014)